In This Article:
As global markets continue to navigate the complexities of rising inflation and shifting trade policies, U.S. stock indexes have climbed toward record highs, with growth stocks leading the charge. In this environment, companies with high insider ownership can offer unique insights into potential future performance, as insiders often have a vested interest in the company's success and may align their strategies accordingly.
Top 10 Growth Companies With High Insider Ownership
| Name | Insider Ownership | Earnings Growth |
| Seojin SystemLtd (KOSDAQ:A178320) | 32.1% | 39.9% |
| Clinuvel Pharmaceuticals (ASX:CUV) | 10.4% | 26.2% |
| SKS Technologies Group (ASX:SKS) | 29.7% | 24.8% |
| Pricol (NSEI:PRICOLLTD) | 25.4% | 25.2% |
| Laopu Gold (SEHK:6181) | 36.4% | 39.1% |
| Pharma Mar (BME:PHM) | 11.9% | 45.4% |
| HANA Micron (KOSDAQ:A067310) | 18.3% | 119.4% |
| Plenti Group (ASX:PLT) | 12.7% | 120.1% |
| Fulin Precision (SZSE:300432) | 13.6% | 71% |
| Findi (ASX:FND) | 35.8% | 133.7% |
We'll examine a selection from our screener results.
Pharma Mar
Simply Wall St Growth Rating: ★★★★★★
Overview: Pharma Mar, S.A. is a biopharmaceutical company focused on the research, development, production, and commercialization of bio-active principles for oncology across various countries including Spain, Italy, Germany, Ireland, France, the rest of the EU and the United States; it has a market cap of approximately €1.71 billion.
Operations: The company generates revenue primarily from its oncology segment, which amounts to €154.75 million.
Insider Ownership: 11.9%
Revenue Growth Forecast: 23.8% p.a.
Pharma Mar shows potential as a growth company with high insider ownership. Its earnings are forecast to grow significantly at 45.4% annually, outpacing the Spanish market's 7.3%. Revenue is also expected to rise by 23.8% per year, exceeding the market average of 5.2%. Despite a volatile share price and reduced profit margins from last year, it trades at 30.3% below its estimated fair value, indicating possible undervaluation amidst strong growth prospects.
-
Delve into the full analysis future growth report here for a deeper understanding of Pharma Mar.
-
The valuation report we've compiled suggests that Pharma Mar's current price could be inflated.
BICO Group
Simply Wall St Growth Rating: ★★★★☆☆
Overview: BICO Group AB (publ) is a bioconvergence company with operations in North America, Europe, Asia, and internationally, and has a market cap of SEK2.93 billion.
Operations: BICO Group generates revenue from its operations across North America, Europe, Asia, and other international markets.